Detail akcie Eisai online

Business Summary: Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Financial Summary: BRIEF: For the fiscal year ended 31 March 2024, Eisai Co Ltd revenues decreased less than 1% to Y741.75B. Net income decreased 23% to Y42.41B. Revenues reflect Pharmaceutical Business segment increase of 5% to Y691.46B, America segment increase of 6% to Y253.76B, Europe segment increase of 5% to Y90.53B, Others segment increase of 3% to Y61.74B, also reflect Other Business segment decrease of 16% to Y50.29B, Japan segment decrease of 10% to Y226.45B.